Sanofi India Introduces Pre-Diagnostic AI Tool for Rare Disease Detection
Advertisement
The AI-supported tool can analyse symptoms, medical history, and laboratory findings to generate the top five likely diagnoses from a database covering 310 rare diseases.
Sanofi India has introduced a wider clinical push for AccelRare, a digital pre-diagnostic tool that has been developed to assist doctors in narrowing down suspected rare diseases in children within minutes.
The AI-supported tool can analyse symptoms, medical history, and laboratory findings to generate the top five likely diagnoses from a database covering 310 rare diseases.
Milan Choksey, Medical Lead for Rare Diseases Business at Sanofi India, said rare conditions frequently resemble routine childhood illnesses during the early stages, making timely identification difficult in busy clinical settings.
“The initial identification and first consult with the doctor is always late,” he said, adding that by the time many children receive the correct diagnosis, permanent damage may already have occurred.
The web-based platform is available free of cost and does not require registration. Doctors can enter anonymised patient information, including symptoms, medical background, and test reports.
The system then generates probable disease matches with an 88 per cent diagnostic accuracy rate. In addition to suggesting likely conditions, the tool also provides disease summaries, recommended follow-up investigations, and referral information for government-recognised centres specialising in rare diseases.
“This matters because as a physician, I know what it means to face a child with unexplained hepatosplenomegaly or persistent thrombocytopenia – symptoms that in a busy, general paediatric practice seeing hundreds of children every week, can so easily be attributed to a common infection like dengue or a routine haematological finding. The clinical reality is that rare diseases hide in plain sight,” Choksey said.
Sanofi stated that AccelRare was co-developed and validated by 67 rare disease experts across 13 international rare disease networks. The platform runs on MedVir technology, which is certified in Europe as a Class I medical device.
In India, the tool has been approved as a web-based pre-diagnostic platform for suspected rare diseases and classified as a Class A medical device under local regulations.
Stay tuned for more such updates on Digital Health News
